Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections

Francesco Blasi, Paolo Tarsia, Roberto Cosentini, Mario Cazzola, Luigi Allegra

Research output: Contribution to journalArticlepeer-review


The impact of respiratory infections on public health is increasing and lower respiratory tract infections are a major cause of morbidity and mortality. We are also facing a worldwide burst of antibiotic bacterial resistance. The new fluoroquinolones have an excellent spectrum covering the most important respiratory pathogens, including atypical and 'typical' pathogens. Pharmacokinetic and dynamic properties of the new fluoroquinolones have a significant impact on their clinical and bacteriological efficacy. They cause a concentration-dependent killing with a sustained postantibiotic effect. Fluoroquinolones combine exceptional efficacy with cost-effectiveness. Not surprisingly, different guidelines have inserted these agents among the drugs of choice in the empirical therapy of community-acquired pneumonia. This review discusses the more recent data on bacteriological and clinical activity and critically analyses the risks of a potential overuse of this valuable new class of drugs.

Original languageEnglish
Pages (from-to)1165-1177
Number of pages13
JournalExpert Opinion on Investigational Drugs
Issue number7
Publication statusPublished - Jul 1 2003


  • Antimicrobial resistance
  • Community-acquired respiratory infections
  • Fluoroquinolones
  • Pharmacokinetic

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections'. Together they form a unique fingerprint.

Cite this